Skip to content

13F-HR filed by SymBiosis Capital Partners, LLC

SymBiosis Capital Partners, LLC filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-12, with 11 holding rows worth $109,495,134.

Accession
0002006045-26-000002
Filed
2026-02-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2025

A holdings report, 11 entries on the cover page, a total value of $109,495,134 stated on the cover page (in dollars after the unit check, H1), rows summing to $109,495,134 with VALUE read as dollars as filed, 13F file number 028-26251. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
EVOMMUNE INC30054Y107COMMON STOCK1,280,778$21,926,919dollars as filed
VERASTEM INC92337C203COMMON STOCK2,000,000$15,440,000dollars as filed
AMPLITECH GROUP INC03211Q200COM2,555,000$13,234,900dollars as filed
PRECIGEN INC74017N105COM3,000,000$12,540,000dollars as filed
INVENTIVA SA46124U107ADS2,600,000$12,090,000dollars as filed
NUVATION BIO INC COM CL A67080N101Stock1,250,000$11,200,000dollars as filed
RANI THERAPEUTICS HLDGS INC753018100CMN6,300,000$8,505,000dollars as filed
AARDVARK THERAPEUTICS INC002942100COM476,595$6,255,309dollars as filed
CLENE INC185634201COM NEW770,495$4,522,806dollars as filed
GENERATION BIO CO37148K209COM NEW665,000$3,777,200dollars as filed
SURROZEN INC86889P117*W EXP 08/01/203150,000$3,000dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0002006045-26-000002this filing2026-02-12acceptance time not in the bulk data set